Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease~* Age: \>18yo~* Stable Hemoglobin (Hgb) for 1 month on stable dose of erythropoietin for 1 month (defined as erythropoietin dose within 15% of previous months erythropoietin dose)~* Unchanged maintenance oral or intravenous (IV) iron therapy for 1 month~* Serum 25-hydroxy Vitamin D levels \< 30 ng/mL~* History of 25-hydroxy Vitamin D levels \< 30 ng/mL currently on ergocalciferol replacement~Exclusion Criteria:~* On hemodialysis~* Chronic kidney disease 5~* Hypercalcemic (Calcium level \> 11mg/dL)~* Pregnant female~* Iron deficient (iron saturation \< 20%, Ferritin \< 100ng/mL)~* Presence of active malignancy~* Presence of active infections~* Presence of active inflammatory properties~* Presence of blood dyscrasias~* Active bleeding or bleeding within the past 3 months (other than menses)~* B12 deficiency~* Folate deficiency~* Blood transfusion during participation~* Parathyroid levels exceeding the expected levels allowed for the stage of a subjects Chronic kidney disease (Target Parathyroid in: Chronic kidney disease 3 35-70 pg/mL, Chronic kidney disease 4 70-110 pg/mL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol supplementation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).